The Scientist

» FDA and disease/medicine

Most Recent

Once implanted in mice, the edited stem cells produced normal hemoglobin.

0 Comments

image: Pet Meds Adapted from Human Therapies

Pet Meds Adapted from Human Therapies

By | October 1, 2016

Companies focused on developing treatments for dogs, cats, and horses are bringing a diverse array of products to the pet medicine market.

0 Comments

image: Techniques for Assessing Genomic Copy Number Variations

Techniques for Assessing Genomic Copy Number Variations

By | October 1, 2016

As the importance of genomic copy number variations for health and disease becomes clearer, researchers are creating new ways to detect these changes in the genome.

0 Comments

image: Genes Linked to Dogs’ Sociability with People

Genes Linked to Dogs’ Sociability with People

By | September 30, 2016

Genetic variants on chromosome 26 appears to play a role in a dog’s tendency to turn to people for help.

0 Comments

image: Broadly Neutralizing Antibodies in HIV Patients

Broadly Neutralizing Antibodies in HIV Patients

By | September 28, 2016

Researchers identify aspects of the patient, the virus, and the infection itself that influence whether a person with HIV will produce broadly neutralizing antibodies.

0 Comments

image: Q&A: From FDA to Industry

Q&A: From FDA to Industry

By | September 27, 2016

Among a subset of US Food and Drug Administration regulators who leave the agency, more than half go to work for pharmaceutical companies, researchers report.

1 Comment

The National Institutes of Health is hosting a two-day conference on how the virus affects infants and children. The take-home message so far: microcephaly is but one of many potential problems for Zika-exposed fetuses.

0 Comments

image: Feds Demand More Clinical Trial Reporting

Feds Demand More Clinical Trial Reporting

By | September 19, 2016

Expanded US Health and Human Services rules will require the results of more human studies to be made public.

1 Comment

image: Conditional FDA Approval for Fatal-Disease Drug

Conditional FDA Approval for Fatal-Disease Drug

By | September 19, 2016

The agency OKs Sarepta Therapeutics’s treatment for Duchenne muscular dystrophy through its accelerated approval pathway, which requires a confirmatory clinical trial.

0 Comments

Scientists estimate the risk to fetuses exposed to the virus in utero.

0 Comments

Popular Now

  1. Opinion: Why I Published in a Predatory Journal
    News & Opinion Opinion: Why I Published in a Predatory Journal

    My “colleagues” and I at the fictitious Arthur Vandelay Urological Research Institute were surprised to find our bogus “uromycitisis” case report swiftly accepted, with only minor revisions requested.

  2. Consilience, Episode 3: Cancer, Obscured
  3. A History of Screening for Natural Products to Fight Cancer
  4. March for Science: Dispatches from Washington, DC
AAAS